Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, highlights the Company's CEO, Dr. Lynn... Read More

Webcast Replay Available on Ensysce's Investor Relations Website SAN DIEGO, CA / ACCESSWIRE / April 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the Company's webcast presentation and discussion during the Noble Capital... Read More

SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose, today announced its participation in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. Dr. Lynn Kirkpatrick, Chief... Read More

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and... Read More

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an... Read More

PF614-MPAR program receives FDA guidance SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a ‘Next Generation' opioid analgesic with... Read More

Publication Details Positive Results of Clinical Study PF614-102 SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (OTC PINK:ENSCW) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced online publication of its manuscript entitled, "Clinical evaluation of PF614, a novel TAAP (TM) prodrug of oxycodone,... Read More

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the... Read More

PF614-MPAR recognized as potential medical breakthrough SAN DIEGO, CA / ACCESSWIRE / February 6, 2024 / Ensysce Biosciences, Inc . (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced they have been selected to present one of the top 12 best Flash Talks in the Trailblazer Session at the 2024 American Association of Pain... Read More

PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the completion of a constructive End of Phase 2 meeting with the Food and Drug Administration (FDA) regarding its lead ‘Next... Read More

SAN DIEGO, CA / ACCESSWIRE / January 25, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Geoff Birkett, Chief Commercial Officer of Ensysce, will present a poster entitled "PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™)... Read More

FDA acknowledges significant potential impact of MPAR's oral overdose protection SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced receipt of notice from the U.S Food and Drug Administration (FDA) that it has granted Breakthrough Therapy... Read More

SAN DIEGO, CA / ACCESSWIRE / January 8, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. Dear Fellow Shareholders, I am very pleased to provide you with an update on the outstanding progress we made over the last... Read More

SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to lack of the required quorum. A quorum consists of one third of the outstanding shares of our common stock (present in person... Read More

Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity Reduction PF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024 SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its... Read More

PHOENIX, AZ / ACCESSWIRE / December 11, 2023 / The Stock Day Podcast welcomed Ensysce Biosciences (NASDAQ:ENSC) ("the Company"), a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs.CEO of the Company, Dr. Lynn Kirkpatrick, joined Stock Day host Matthew Dunehoo. Dunehoo began the interview by asking about the Company's background and current projects. "Ensysce Biosciences is... Read More

Additional Funding from Investors Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / November 29, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced today that it has completed its previously announced private placement under a securities purchase agreement (the "SPA") with investors... Read More

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment SAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB ("OncoZenge") (STO:ONCOZ), a... Read More

Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 Trial Results Expected in December 2023 SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the PF614-201 study, ‘A Randomized, Double-Blind, Placebo-Controlled Crossover... Read More

PF614-201 Clinical Study Results Expected by End of Year SAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the third quarter of 2023. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We continue to execute... Read More

Additional Funding from Investor Cohort Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / October 24, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced today that it has entered into a securities purchase agreement (the "SPA") with investors ("Investors") in the form of... Read More

Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR Formulation SAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced Dr. Dolly Jacob, Director Integrated Development Services of Quotient Sciences, will present the... Read More

A showcase of PF614 and PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has posted to the Company's Corporate and Investor Relations website a video highlighting its PAINWeek Symposium entitled, "Severe Pain, Next Generation Solutions:... Read More

Geoff Birkett, CCO of Ensysce, to Chair Meeting, Deliver Opening Remarks and Present a Case Study on Drug Launch Process SAN DIEGO, CA / ACCESSWIRE / October 3, 2023 / Ensysce Biosciences, Inc . (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the Company will present at the Fierce New Product Planning Summit 2023... Read More

Study Initiation Brings PF614 One Necessary Step Closer to Phase 3 Trial Results Expected Before Year End 2023 SAN DIEGO, CA / ACCESSWIRE / September 26, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Site Initiation Visit (SIV) was completed for the PF614-201 study, ‘A Randomized,... Read More

SAN DIEGO, CA / ACCESSWIRE / September 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced they will host a Research and Development ("R&D") FAQ Session to discuss educational session held at PAINWeek where they presented their approach to delivering the Next Generation of analgesics.... Read More

Positioning Company to Commence Commercialization Strategy SAN DIEGO, CA / ACCESSWIRE / September 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that two scale up manufactures have been completed for the Company's lead drug candidate PF614, a next generation pain medicine to treat... Read More

Leading Experts Presenting New Clinical Approaches to Treat Severe Pain at PAINWeek Symposium SAN DIEGO, CA / ACCESSWIRE / September 7, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is presenting clinical data at PAINWeek, the leading US pain conference, today, September 7, 2023, in Las Vegas, NV.... Read More

SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its management has been invited to present at the H.C. Wainwright 25 th Annual Global Investment Conference (the "conference") taking place in New York, NY on September 11-13, 2023. The... Read More

Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain and Next Generation Solutions SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will host a luncheon symposium and present their recent clinical data at PAINWeek on September 7-8, 2023... Read More

Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023. Dr. Lynn Kirkpatrick, Chief Executive... Read More

Approval of Study Represents Progression Toward Full Phase 3 Evaluation of PF614 Study to Assess PF614 Time of Onset for Severe Pain Relief SAN DIEGO, CA / ACCESSWIRE / August 8, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Investigational Review Board ("IRB") approval of... Read More

Engagement to aid expansion of the use of TAAP and MPAR ® as well as the rapid development and commercialization of Ensysce's next generation opioids SAN DIEGO, CA / ACCESSWIRE / July 26, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has engaged Alacrita Consulting ("Alacrita"), a pharma and biotech consulting... Read More

Featured Presentation on ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose' SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release... Read More

SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the equity requirement in Listing Rule 5550(b)(1), as described in the Hearing Panel's... Read More

SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website . The updated investor presentation reflects updated financials and Company milestones as of today. The updated investor presentation... Read More

Chief Medical Officer, Dr. William Schmidt, to Present at the CPDD 85 th Annual Scientific Meeting Chief Commercial Officer, Geoff Birkett, to Present Opening Address at EPHMRA 2023 Annual Conference SAN DIEGO, CA / ACCESSWIRE / June 6, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced two upcoming presentations in... Read More

Recently Completed Successful Ground-Breaking Study on Overdose Protection Recently Completed $7 Million Public Offering SAN DIEGO, CA / ACCESSWIRE / May 15, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the first quarter of 2023 following the recently completed,... Read More

SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to... Read More

SAN DIEGO, CA / ACCESSWIRE / May 10, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today announced the pricing of a public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to... Read More

Represents Major Milestone Towards Launch of PF614-MPAR PF614-MPAR on Track to be the First Drug to Protect Against Overdose SAN DIEGO, CA / ACCESSWIRE / May 9, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced completion of PF614-MPAR-101, a clinical study examining the Company's first pain medication with... Read More

Global QUOTIENT LIFE SCIENCES Webinar Today, April 19, 2023 at 11:30am ET SAN DIEGO, CA / ACCESSWIRE / April 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Company's CEO, Dr. Lynn Kirkpatrick will be participating in ‘Strategies for Achieving Regulatory Milestones Faster: An... Read More

Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website . As a reminder, the... Read More

Reduced Drug Liking of PF614 versus Oxycodone SAN DIEGO, CA / ACCESSWIRE / April 3, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced positive results from a key study on the oral human abuse potential of PF614, a potential next generation pain medicine. The study met all key endpoints and showed PF614 had significantly lower scores of "Drug Liking" than the oxycodone comparator at... Read More

Corporate Update Call to be Held Tuesday, April 11, 2023 SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented,... Read More

Data Demonstrates Exceptional Safety Profile of PF614-MPAR, the Industry's First Overdose Protection Pain Product SAN DIEGO, CA / ACCESSWIRE / March 22, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced the completion of enrollment in the final stage of the Phase 1 study,... Read More

Ensysce Biosciences and Quotient Sciences Showcase a Unique Collaboration SAN DIEGO, CA / ACCESSWIRE / March 6, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced Dr. Lynn Kirkpatrick, Chief Executive Officer, is a featured speaker at a lunch seminar on... Read More

Company Remains on Track to Report Results the End of March SAN DIEGO, CA / ACCESSWIRE / February 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the database lock on February 24, 2023 for the oral Human Abuse Potential (HAP) study of PF614.... Read More

Answers Recently Asked Questions SAN DIEGO, CA / ACCESSWIRE / February 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick, to address the Company's most recent frequently asked... Read More

SAN DIEGO, CA / ACCESSWIRE / February 15, 2023 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that by decision dated February 14, 2023, a Nasdaq Hearings Panel (the "Panel") granted the Company's request for continued listing on The Nasdaq Stock Market ("Nasdaq"),... Read More

SAN DIEGO, CA / ACCESSWIRE / February 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett,... Read More

SAN DIEGO, CA / ACCESSWIRE / February 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of... Read More

SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common... Read More

SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per... Read More

PF614-MPAR to be the Industry's First Overdose Protection Pain Product SAN DIEGO, CA / ACCESSWIRE / January 25, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the initiation of the final stage of the Phase 1 study of PF614-MPAR.... Read More

SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth... Read More

NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research , a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on January 25, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-minute presentations by public company management teams – followed by an... Read More

SAN DIEGO, CA / ACCESSWIRE / January 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. Dear Fellow Shareholders, I want to take this opportunity to thank our... Read More

Data Expected in March 2023 SAN DIEGO, CA / ACCESSWIRE / January 4, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has successfully completed the clinical portion of study PF614-104, ‘A Randomized, Double-Blind, Placebo- and... Read More

PF614-MPAR will be the Industry's First Overdose Protection Pain Product SAN DIEGO, CA / ACCESSWIRE / December 19, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced data demonstrating the overdose protection of its drug product,... Read More

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research , a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Ensysce Biosciences, Inc. (NASDAQ: ENSC). The in-depth 21-page initiation report includes detailed information on the Ensysce Biosciences’ business model, services, industry, valuation, management, and risks. The full research report is available... Read More

SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock (or common stock equivalents in lieu thereof) and... Read More

Completion of Trial Represents Continuing Progress Towards Development of the Industry's First Overdose Protection Pain Product SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC),(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has... Read More

Corporate Update Call to be Held Wednesday, November 16, 2022 SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today reported financial results for the third quarter of 2022. Dr. Lynn Kirkpatrick, Chief... Read More

Acute pain indication may be appropriate, with potential to significantly shorten development path SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced that it received written guidance... Read More

Announces Timing of Corporate Update Call Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia, a Trypsin Activated... Read More

Critical Study to Support Abuse Deterrent Labeling Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the first subjects dosed in the PF614-104 study, ‘A Randomized, Double-blind, Placebo and Active-Controlled, Crossover Study to... Read More

Ensysce Biosciences, Inc. (NASDAQ: ENSC) (OTC Pink: ENSCW) ("Ensysce" or the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced management's participation in the LD Micro Main Event XV conference being held from October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Bel Air, California. The Company's Chief... Read More

Oral Opioid Abuse Being Explored for PF614 Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced the initiation of PF614-104, ‘A... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that management will present during Benzinga's All Access investor event taking place Friday, September 23, 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, is scheduled to host... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the results of the special meeting of stockholders held September 8, 2022. This meeting was held virtually, and the following resolutions were submitted and adopted by the stockholders: The... Read More

Special Meeting to be Held Virtually on Thursday, September 8 th at 9:00 AM PT Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today reminds shareholders to vote on or before the upcoming annual shareholder meeting on Thursday, September 8 th at 9:00 AM... Read More

Partnership further expedites Ensysce's development pipeline Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC) (OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient Sciences, a drug development and manufacturing accelerator, today announced a partnership to support the development and clinical testing of PF614-MPAR.... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the launch of the new Ensysce website at www.ensysce.com . The Company's updated website highlights the TAAP TM and MPAR TM technology platforms, the depth of the team, and our truly unique... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced its participation in the following upcoming conferences: PAINWeek Conference 2022, September 6 - September 9, 2022, in Las Vegas, NV . Dr. Lynn Kirkpatrick, Chief Executive Officer, to chair a... Read More

Completion of Clinical Portion Represents Critical Milestone Towards Commercialization Nasal Opioid Abuse Being Explored for PF614 Data From Trial Expected in September 2022 Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has... Read More

Call to be Held Today, August 17, 2022 at 11am ET Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today released an updated investor presentation to its investor relations website accessible via https://ir.ensysce.com/ . The... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the second quarter 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "With a recently completed $8 million financing, we... Read More

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors ("Investors") for senior secured convertible notes (the... Read More

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~ ~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~ Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the data from the Part B, Bioequivalence... Read More